A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors

Neurology

Volumn 46, Issue 4, 1996, Pages 985-991

  Glantz, M J ^a,d   Cole, B F ^a   Friedberg, M H ^b   Lathi, E ^c   Choy, H ^a   Furie, K ^a   Akerley, W ^a   Wahlberg, L ^a   Lekos, A ^a   Louis, S ^a  

^a BROWN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT VINCENT HOSPITAL   (United States)

^d MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROATE SEMISODIUM;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; FEMALE; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEIZURE; TREMOR; WEIGHT GAIN;

EID: 9244234322     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.4.985     Document Type: Article

References (56)

1. Posner JB. Management of brain metastases. Rev Neurol 1992;148:477-487.
2. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
3. Simonescu MD. Metastatic tumors of the brain. A follow-up study of 195 patients with neurosurgical considerations. J Neurosurg 1960;17:361-373.
4. Paillas JE, Pellet W. Brain metastasis. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. New York: Elsevier, 1976.
5. Posner JB. Clinical manifestations of brain metastases. In: Gilbert HA, Posner JB, Weiss L, eds. Brain metastasis. Boston: GK Hall, 1980:189-207.
6. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981;48:384-394.
7. Byrne TN, Cascino TL, Posner JB. Brain metastases from melanoma. J Neurooncol 1983;1:313-317.
8. Flint G. Seizures and epilepsy. Br J Neurosurg 1988;6:419-421.
9. Cohen N, Strauss G, Lew R, Silver D, Recht L. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988;6:1621-1624.
10. Mahaley MS Jr, Dudka L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 1981;16:399-401.
11. Kikuchi K, McCormick C, Neuwelt EA. Immunosuppression by phenytoin: implications for altered immune competence in brain-tumor patients. J Neurosurg 1984;61:1085-1090.
12. Delattre J, Safai B, Posner JB. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988;38:194-198.
13. Dubinsky S, Newmark ME. Skin rashes after antiepileptic drug use [abstract], Epilepsia 1991;32(suppl 3):17.
14. Boarini DJ, Beck DW, VanGilder JC. Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 1985;16:290-292.
15. Hung S, Hilsenbeck S, Feun L. Seizure prophylaxis with phenytoin in patients with brain metastases [abstract]. Proc Am Soc Clin Oncol 1991;10:A1151.
16. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 1982;45:55-59.
17. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985;48:639-644.
18. Chadwick DW. Valproate monotherapy in the management of generalized and partial seizures. Epilepsia 1987;28(suppl 2): S12-S17.
19. Driefuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37: 379-385.
20. Driefuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989;39:201-207.
21. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991;41:961-964.
22. Willmore LJ, Brugger AM, Shu V, the Depakote Complex Partial Seizure Research Group. Depakote in the treatment of complex partial seizures. A multi-center study [abstract]. Neurology 1994;44(suppl 2):295.
23. Richens A, Davidson DLW, Cartlidge NEF, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994;57:682-687.
24. Goddard GV. Development of epileptic seizures through brain stimulation at low intensity. Nature 1967;214:1020-1021.
25. Schmutz M. Relevance of kindling and related processes to human epileptogenesis. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:505-525.
26. Schmutz M, Klebs K, Baltzer V. Inhibition or enhancement of kindling evolution by antiepileptics. J Neural Transm 1988; 72:245-257.
27. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol 1991;29:356-363.
28. Booth BM, Blow FC. The kindling hypothesis: further evidence from a U.S. national study of alcoholic men. Alcohol 1993;28:593-598.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
30. Cox DR. Regression models and life tables. J R Stat Assoc [B] 1972;34:187-202.
31. Leppik IE. Compliance during treatment of epilepsy. Epilepsia 1988;29(suppl 2):S79-S84.
32. Haque N, Thrasher K, Werk E. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. J Clin Endocrinol Metab 1972;34:44-50.
33. Wassner SJ, Malekzadem MH, Pennisi AJ, et al. Allograft survival in patients receiving anticonvulsant medications Clin Nephrol 1977;8:293-297.
34. Chalk JB, Ridgeway K, Brophy T, Yelland JDN, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984;47:1087-1090.
35. Gambertoglio JG, Holford NH, Kapusnik JE, et al. Disposition of total unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int 1984;25:119-123.
36. Wong DD, Longnecker RG, Liepman M, Baker S, La Vergne M. Phenytoin-dexamethasone: a potential drug interaction [letter]. JAMA 1985;254:2062-2063.
37. Dropcho EJ, Soong S. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41:1235-1239.
38. Warren RD, Bender AR. Drug interactions with antineoplastic agents. Cancer Treat Rep 1977;61:1231-1241.
39. Reich SD, Bachur NR. Alterations in adriamycin efficacy by phenobarbital. Cancer Res 1976;36:3803-3806.
40. Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity. Cancer Chemother Pharmacol 1990;27:226-228.
41. Hansten PD, Horn JR. Drug Interactions and Updates. 6th ed. Philadelphia: Lea & Febiger, 1993.
42. Levin VA, Stearns J, Byrd A, et al. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. J Pharmacol Exp Ther 1979;208:1-6.
43. Muller PJ, Tator CM, Bloom M. The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model. J Neurosurg 1980;52:359-366.
44. Koranyi L, Gero L. Influence of diphenylhydantoin on the effect of streptozocin. BMJ 1979;13:127.
45. Fetell MR, Grossman SA, Balmaceda C, et al. Clinical and pharmacologic study of pre-irradiation taxol administered as a 96 hour infusion in adults with newly diagnosed glioblastoma multiforme (GBM) [abstract]. Proc Am Soc Clin Oncol 1994;13:179.
46. Baker DK, Relling MV, Pui C-H, et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992;10:311-315.
47. Craft AW, Kay HE, Lawson DN, et al. Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia. BMJ 1977;2:1511-1512.
48. Finchum RW, Schottelius DD. Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1979;1:277-283.
49. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 1982;7:57-84.
50. Bollini P, Riva R, Albani F, et al. Decreased phenytoin levels during antineoplastic therapy: a case report. Epilepsia 1983; 24:74-78.
51. Sylvester RK, Lewis FB, Caldwell KC, et al. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycin. Ther Drug Monit 1984;6:302-305.
52. Jarosinski PF, Moslow JA, Alexander MS, et al. Altered phenytoin clearance during intensive treatment for acute lymphoblastic leukemia. J Pediatr 1988;112:996-999.
53. Neef C, Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988;43:372-375.
54. Grossman SA, Sheilder VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 1989;87: 505-510.
55. Dofferhoff ASM, Berendsen HH. Decreased phenytoin level after carboplatin treatment. Am J Med 1990;89:247-248.
56. Ghosh C, Lazarus HM, Hewlett JS, Creger RJ. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. J Neurooncol 1992;12:25-32.